Month: May 2023

First Multi-Center Study Combining the Allurion Program With GLP-1 Therapy Presented at the European Congress on Obesity


Combination therapy led to nearly 19% weight loss at approximately 8 months Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Allurion, a company dedicated to ending obesity, today announced results from a new study that will be presented at the European Congress on Obesity exploring the use of a GLP-1 weight-loss medication with the Allurion Gastric…

Read More

Rejuvenate Bio Announces Data for Gene Therapy RJB-01 in Mitral Valve Disease at 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)


Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio, today announced new data for its gene therapy RJB-01 from a pilot study in canines with myxomatous mitral valve disease (MMVD), at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 16-20, 2023, in Los Angeles, California. RJB-01, expresses…

Read More

Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting


Oral presentation highlights EPI-321 effects on multiple clinically relevant markers – Excerpt from the Press Release: – Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The data were shared in…

Read More

IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas


Study is the Second Clinical Human Trial Using Mobetron with Electron Excerpt from the Press Release: SUNNYVALE, Calif.–(BUSINESS WIRE)–IntraOp Medical Corporation announced the world’s first Phase II Electron FLASH Trial. It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC). It is the second…

Read More

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113


Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases Excerpt from the Press Release: NEWARK, Calif., May 12, 2023 /PRNewswire/ — Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on…

Read More

Celebrating International Clinical Trials Day on May 20th!


May 20th celebrates International Clinical Trials Day, as a time to give thanks and support to all the exceptionally hard-working clinical research pros out there! Their work is like putting together a massive puzzle that maps out the terrain of public health and medicine. We set aside May 20th each year to tip our hats…

Read More

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data


Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter patent for brilaroxazine-lipogel and a separate patent for use in the treatment of psoriasis Excerpt from the Press Release: CUPERTINO, Calif., May 11, 2023…

Read More

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study


Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Excerpt from the Press Release: Carlsbad, CA, May 11, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced…

Read More

Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis


Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition Excerpt from the Press Release: WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous…

Read More

Investment in Ontario drug discovery research will help develop new cancer medicines for patients


OICR announces support for five projects through its Cancer Therapeutics Innovation Pipeline (CTIP) Excerpt from the Press Release: Ontario research teams investigating new ways to treat cancer are taking the crucial next steps to bring their discoveries to patients thanks to support from the Ontario Institute for Cancer Research (OICR). OICR announced it is funding…

Read More